Related Experiment Video

Updated: Jun 7, 2026

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

Src family kinase inhibitor PP2 efficiently inhibits cervical cancer cell proliferation through down-regulating

Lu Kong1, Zhihong Deng, Haiying Shen

  • 1Department of Biochemistry and Molecular Biology, Cancer Institute, Capital Medical University, Beijing, China.

Molecular and Cellular Biochemistry
|November 6, 2010
PubMed

Insights

PP2, a tyrosine kinase inhibitor, effectively reduces cervical cancer cell growth by down-regulating Src and EGFR pathways. This study clarifies PP2's mechanism, showing its potential in targeted cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Tyrosine kinase inhibitors are crucial for targeted cancer therapy, but their mechanisms and applications are not fully understood.
  • Previous research demonstrated PP2, a Src family non-receptor tyrosine kinase (nRTK) inhibitor, inhibits cervical cancer progression.
  • Further investigation is needed to elucidate the precise mechanisms of PP2 in cervical cancer.

Purpose of the Study:

  • To explore the mechanism of PP2 in inhibiting cervical cancer cell growth.
  • To compare the suppressive effects of PP1, PP2, and PP3 on cervical cancer cells.
  • To investigate the impact of PP2 on specific signaling pathways and cell cycle regulation.

Main Methods:

  • Cell proliferation was assessed using MTT assays on HeLa and SiHa cervical cancer cell lines.
  • Western blotting was used to analyze the expression levels of phosphorylated Src (pSrc-Y416) and epidermal growth factor receptor (pEGFR-Y845, pEGFR-Y1173).
  • Cell cycle regulatory proteins, including p21(Cip1), p27(Kip1), cyclins, and cyclin-dependent kinases (CDKs), were examined.

Main Results:

  • PP2 demonstrated the most potent time- and dose-dependent inhibition of cervical cancer cell proliferation compared to PP1 and PP3.
  • PP2 significantly down-regulated pSrc-Y416, pEGFR-Y845, and pEGFR-Y1173 expression.
  • PP2 induced cell cycle arrest by up-regulating p21(Cip1) and p27(Kip1) and down-regulating cyclins and CDKs.

Conclusions:

  • The Src and EGFR pathways play distinct roles in cervical cancer cell proliferation.
  • PP2 effectively inhibits cervical cancer cell proliferation by simultaneously reducing Src and EGFR activity.
  • PP2 shows promise as a targeted therapeutic agent for cervical cancer.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.